Power Law company profile

Selecta Biosciences

Biotech & Life Sciences · Watertown, United States · Founded 2008 · IPO 2016 Thoroughbred

Pioneering RNA cell therapy for autoimmune disease

Valuation

$51M

Market cap · 2026

Revenue

$2.8M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

9 investors on Selecta Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage

Flagship Pioneering

Polaris Partners

Series B+ 7 investors entered at this stage

Osage University Partners

OrbiMed

Ridgeback Capital

Sanofi-Genzyme BioVentures

+ND Capital

Rusnano

Nano Dimension

Global footprint

Where Selecta Biosciences has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

60 monthly visits
across markets

🇺🇸 United States2666.7%

Top 1 markets shown

Market sentiment

What the market is saying about Selecta Biosciences

An AI-synthesized read of the highest-engagement posts about Selecta Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Selecta Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles